Clinical Trial Update: Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial to evaluate Ivonescimab before surgery for high-risk localized clear cell renal cell carcinoma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING